Results 111 to 120 of about 16,492 (195)

Proprotein convertase subtilisin/ kexin type 9 levels and arterial function

Atherosclerosis, 2018
Koutagiar, I., Vlachopoulos, C., Terentes-Printzios, D., Skoumas, J., Skliros, N., Rigatou, A., Ioakeimidis, N., Pantou, S., Georgakopoulos, C., Miliou, A., Tousoulis, D.   +10 more
openaire   +2 more sources

Transforming growth factor beta reduces proprotein convertase subtilisin/kexin type 9 in the supernatant of hepatic stellate cells. [PDF]

World J Hepatol
Bundschuh J, Neumann M, Zimny S, Spirk M, Buechler C.   +4 more
europepmc   +1 more source

Epithelial PCSK6 Promotes Proliferation and Decreases Collagen Deposition by Fibroblasts Potentially via MMP Activation. [PDF]

Int J Mol Sci
Tian Q, Dijkhuis A, Remmerswaal EBM, Aberson H, Crestani B, van der Poll T, Spek CA, Duitman JW.   +7 more
europepmc   +1 more source

Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction. [PDF]

Int J Cardiol Heart Vasc
Horbach T, Wenzl FA, Manka R, Räber L, Carballo D, Keller T, Sossalla S, Ruschitzka F, von Eckardstein A, Stähli BE, Lüscher TF, Klingenberg R.   +11 more
europepmc   +1 more source

Effects of lipid-lowering drugs on epilepsy and its subtypes: A drug-target Mendelian randomization study. [PDF]

Medicine (Baltimore)
Wang Y, Huang S.
europepmc   +1 more source

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study. [PDF]

J Int Med Res
Wang Y, Liu X, Huang S.
europepmc   +1 more source

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]

Rev Assoc Med Bras (1992)
Costa ALDS, Santos JED, Salgado Junior W, Bertoncini-Silva C, Bizari L, Moura GSPL, Liberatore Junior RDR, Zorzo RA, Suen VMM.   +8 more
europepmc   +1 more source

New-onset vitiligo following proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect. [PDF]

JAAD Case Rep
Umaña Mejia CA, Olvera Morales M, Jurado Orozco A, Burgos JD.   +3 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]

Rev Cardiovasc Med
Theofilis P, Vlachakis PK, Karakasis P, Iliakis P, Pamporis K, Oikonomou E, Dimitriadis K, Tsioufis K, Tousoulis D.   +8 more
europepmc   +1 more source

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial. [PDF]

BMJ Open
Chen Z, Ma S, Zhang J, Zhang R, Zhou M, Li C, Chen Y, Wang H, He Y, REPRESS trial investigator.   +9 more
europepmc   +1 more source